Subbiah J, Oh J, Kim KH, Shin CH, Park BR, Bhatnag. A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine. NPJ Vaccines. 2022 Jun 29;7(1):68
We developed a new chimeric M2e and H3 hemagglutinin (HA) stalk protein vaccine (M2e-H3 stalk) by genetic engineering of modified H3 stalk domain conjugated with conserved M2e epitopes to overcome the drawbacks of low efficacy by monomeric domain-based universal vaccines. M2e-H3 stalk protein expressed and purified from Escherichia coli was thermostable, displaying native-like antigenic epitopes recognized by antisera of different HA subtype proteins and influenza A virus infections. Adjuvanted M2e-H3 stalk vaccination induced M2e and stalk-specific IgG antibodies recognizing viral antigens on virus particles and on the infected cell surface, CD4+ and CD8+ T-cell responses, and antibody-dependent cytotoxic cell surrogate activity in mice. M2e-H3 stalk was found to confer protection against heterologous and heterosubtypic cross-group subtype viruses (H1N1, H5N1, H9N2, H3N2, H7N9) at similar levels in adult and aged mice. These results provide evidence that M2e-H3 stalk chimeric proteins can be developed as a universal influenza A virus vaccine candidate for young and aged populations.
See Also:
Latest articles in those days:
- Global pattern and determinant for interaction of seasonal influenza viruses 2 hours ago
- Spatio-temporal dynamics and drivers of highly pathogenic avian influenza H5N1 in Chile 1 days ago
- [preprint] Avian Influenza Virus Infections in Felines: A Systematic Review of Two Decades of Literature 1 days ago
- Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe 1 days ago
- Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older 1 days ago
[Go Top] [Close Window]